Assenagon Asset Management S.A. Sells 13,220 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)

Assenagon Asset Management S.A. lowered its position in Protara Therapeutics, Inc. (NASDAQ:TARAFree Report) by 45.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,831 shares of the company’s stock after selling 13,220 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Protara Therapeutics were worth $26,000 as of its most recent SEC filing.

Separately, Virtu Financial LLC bought a new position in shares of Protara Therapeutics during the 2nd quarter worth $30,000. Institutional investors and hedge funds own 46.44% of the company’s stock.

Protara Therapeutics Trading Up 7.8 %

Shares of Protara Therapeutics stock opened at $2.89 on Friday. Protara Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $4.18. The stock’s fifty day moving average price is $2.05 and its 200-day moving average price is $1.90. The firm has a market cap of $32.83 million, a P/E ratio of -0.47 and a beta of 1.52.

Protara Therapeutics Company Profile

(Free Report)

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease.

Read More

Want to see what other hedge funds are holding TARA? Visit to get the latest 13F filings and insider trades for Protara Therapeutics, Inc. (NASDAQ:TARAFree Report).

Institutional Ownership by Quarter for Protara Therapeutics (NASDAQ:TARA)

Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with's FREE daily email newsletter.